agena-bioscience-logo
  • Technology
  • Applications
  • Resources
  • Support
  • Company
  • Contact
EN - Global CN - 中国

menu

agena-bioscience-logo agena-bioscience-logo Close
  • Home
  • Technology
  • Applications
    • Pharmacogenetics
    • Liquid Biopsy
    • Mutation Profiling
    • Hereditary Genetics
    • Methylation
    • Sample Integrity
    • Specimen Validity
  • Services
    • Assays by Agena
    • Certified Service Providers
  • Resources
    • Product Literature
    • Publication Library
  • Support
    • Service Plans
    • Distributors
    • Certified Service Providers
  • Company
    • Careers
    • Press
  • Contact
  • Customer Support Portal
  • Home
  • Technology
  • Applications
    • Pharmacogenetics
    • Mutation Profiling
    • Liquid Biopsy
    • Hereditary Genetics
    • Methylation
    • Sample Integrity
    • Specimen Validity
  • Services
    • Assays by Agena
    • Certified Service Providers
  • Resources
    • Product Literature
    • Publication Library
  • Support
    • Service Plans
    • Distributors
    • Certified Service Providers
  • Company
    • Careers
    • Press
  • Contact
  • Customer Support Portal

Phone: (858) 882-2800

Home / Resources / Publication Library

Search Results for: Mutation Profiling

Search All publications

How recent?
  • Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases
  • Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma
  • HER2 as a target in invasive urothelial carcinoma
  • PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study
  • Molecular-Guided Therapy for Melanoma in Canada: Overview of Current Practices and Recommendations
  • Importance of driver gene mutation assessment and targeted therapy for patients with early stage non small cell lung cancer and non R0 resection
  • Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer
  • Predictive [18F]-FDG PET/CT-Based Radiogenomics Modelling of Driver Gene Mutations in Non-small Cell Lung Cancer
  • Analysis of IDH and EGFR as Biomarkers in Glioblastoma Multiforme: A Case-Control Study
  • Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma
12345...102030...»
Products
  • Technology
  • Applications
  • Custom Assays
Resources
  • Product Literature
  • Publication Library
  • ISO Certifications
  • Patents
    Support
    • Support Contacts
    • Service Plans
    • Certified Service Providers
    • Distributors
    • Customer Support Portal
Company
  • About Us
  • Careers
  • Contact
footer-logo
Agena Bioscience

4755 Eastgate Mall,
San Diego, CA 92121

(877) 443-6663

With exception of the MassARRAY Dx, all other products are For Research Use Only. Not for use in diagnostic procedures.
© 2020-2025 Agena Bioscience, Inc. All rights reserved. Agena Bioscience is a subsidiary of Mesa Labs, Inc.

  • footer-mesalabs-logo
  • footer-protein-logo
  • footer-gke-logo
  • Privacy Policy
  • Website Terms & Conditions
  • Product Terms & Conditions
  • Warranty